Inactive Instrument

Roche Holding AG Stock Xetra

Equities

RHO

CH0012032113

Pharmaceuticals

Financials

Sales 2024 * 60.04B 65.72B 61.33B 89.69B Sales 2025 * 63.83B 69.88B 65.21B 95.36B Capitalization 178B 195B 182B 266B
Net income 2024 * 13.31B 14.57B 13.6B 19.89B Net income 2025 * 14.75B 16.15B 15.07B 22.04B EV / Sales 2024 * 3.21 x
Net Debt 2024 * 14.24B 15.59B 14.55B 21.27B Net Debt 2025 * 8.17B 8.94B 8.34B 12.2B EV / Sales 2025 * 2.92 x
P/E ratio 2024 *
13 x
P/E ratio 2025 *
11.8 x
Employees 103,605
Yield 2024 *
4.4%
Yield 2025 *
4.55%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 49 02-12-31
Chairman 57 07-12-31
Director of Finance/CFO 57 11-03-31
Members of the board TitleAgeSince
Director/Board Member 72 15-03-02
Director/Board Member 59 -
Director/Board Member 65 95-12-31
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company